Covid: collaborations between competing laboratories in the vaccine race are on the rise
Recently, Sanofi announced a partnership with Johnson & Johsnon to help produce doses of its vaccine in Europe.
AFP - JOEL SAGET
Text by: RFI Follow
2 min
The German laboratory CureVac has signed an agreement with Novartis.
The Swiss pharmaceutical giant will contribute to the production this year of the messenger RNA vaccine that the start-up is developing.
This announcement, today, extends the list of collaborations between competing laboratories in the race for the vaccine against Covid-19.
Publicity
Read more
Recently, Sanofi announced a partnership with
Johnson & Johsnon
to help produce doses of its vaccine in Europe.
At the beginning of the year, it was for another American, Pfizer and the German BioNTech, that the French had decided to work
.
In total, Sanofi has therefore entered into three partnerships, because in April 2020, it partnered with GSK.
It was therefore not a question of producing for a competitor but of jointly developing a vaccine, a vaccine still in the testing phase.
Johnson & Johnson's vaccine will also be partly produced by compatriot Merck, while Pfizer and BioNTEch, beyond Sanofi, have also called on Novartis.
It's not easy to navigate this spider's web.
Generally, the groups that originate the vaccines keep control over the production of the active ingredients. The others package and bottle them. However, this scheme does not apply to all alliances.
The case of CureVac is similar to an indirect collaboration between large groups through this biotech.
GSK is involved in the development, Novartis is to manufacture the active ingredient and Bayer will provide support, among other things, in production.
Newsletter
Receive all international news directly in your mailbox
I subscribe
Follow all the international news by downloading the RFI application
google-play-badge_FR
Vaccines
Coronavirus